Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Specify Company / Ticker to Get the Summary
Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Candel Therapeutics Inc
CADLCurrent price
9.17 USD
+0.46 USD (+5.28%)
Last closed
8.80 USD
Company
www.candeltx.com
ISIN
US1374041093
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Capitalization
134 286 192 USD
Yield for 12 month
+559.71 %
1Y
3Y
5Y
10Y
15Y
CADL
Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma. The company also develops CAN-3110, which is in Phase I clinical trials for the treatment of recurrent high-grade glioma. It also develops the"enLIGHTEN Discovery Platform, a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. Candel Therapeutics, Inc. was incorporated in 2003 and is headquartered in Needham, Massachusetts. Address: 117 Kendrick Street, Needham, MA, United States, 02494
Check your investment idea
Find the best to beat the market
TSLA
Tesla Motors
AAPL
Apple
MSFT
Microsoft
Analytics
WallStreet Target Price
11.00 USDP/E ratio
–Dividend Yield
–Current Year
+31 000 USD
Last Year
+125 000 USD
Current Quarter
–
Last Quarter
–
Current Year
-23 980 000 USD
Last Year
-862 000 USD
Current Quarter
–
Last Quarter
-249 000 USD
Key Figures CADL
1 year
3 years
5 years
10 years
EBITDA
-34 658 000 USD
Operating Margin TTM
PE Ratio
–
Return On Assets TTM
-52.31 %
PEG Ratio
–
Return On Equity TTM
-480.68 %
Wall Street Target Price
11.00 USD
Revenue TTM
31 000 USD
Book Value
0.44 USD
Revenue Per Share TTM
Dividend Share
–
Quarterly Revenue Growth YOY
–
Dividend Yield
–
Gross Profit TTM
-20 662 000 USD
Earnings per share
-1.73 USD
Diluted Eps TTM
-1.73 USD
Most Recent Quarter
III 2024
Quarterly Earnings Growth YOY
–
Profit Margin
–
Dividend Analytics CADL
Max Ratio
>10 - expected double digit dividend yield on cost over 10Y >5 - expected 5-9 dividend yield on cost over 10Y <5 - expected <5 dividend yield on cost over 10Y MaxRatio is an estimated 10Y dividend yield on cost calculated by combining the current dividend yield with the 5-year & 10-year average dividend growth rate, projected over the next 10 years discounted based on current Financial Score. It provides a projected outlook on future dividend returns.
–5Y Dividend Growth
–Consecutive Years
–5Y Average Payout Ratio
–Dividend History CADL
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
–
Ex Dividend Date
–
Forward Annual Dividend Yield
–
Last Split Factor
–
Payout Ratio
–
Last Split Date
–
Dividend Date
–
Stock Valuation CADL
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
–
Forward PE
40.9836
Enterprise Value Revenue
821.9774
Price Sales TTM
436.4156
Enterprise Value EBITDA
-0.0084
Price Book MRQ
30.408
Financials CADL
1 year
3 years
5 years
10 years
15 years
| Results | 2019 | Dynamics |
* The data for this period has not yet been published
Technical indicators CADL
For 52 weeks
1.02 USD
14.30 USD
50 Day MA
5.90 USD
Shares Short Prior Month
2 096 617
200 Day MA
5.65 USD
Short Ratio
7.72
Shares Short
2 179 182
Short Percent
8.06 %
BeatStart